This is single arm study to evaluate an escalation anti-fungal prophylaxis protocol for
patients undergoing allogeneic stem cell transplantation. For all patients without documented
proven or probable invasive fungal disease (IFD), patients will receive fluconazole during
the treatment in the laminar air flow units (LAF). After discharged from LAF units, patients
will receive anti-mold prophylaxis in case of haplo-identical or HLA-matched unrelated donor
transplantation to d+100 without active acute GVHD (aGVHD). In case of active aGVHD, the
prophylaxis treatment will be extended until recovery of aGVHD and tapering of
immunosuppression. In case of HLA-matched sibling donor, fluconazole will be continued to
d+100 and anti-mold prophylaxis will be given in case of active aGVHD.